When chronic kidney disease, heart disease, obesity, and diabetes converge in a single patient, treating each condition in isolation is no longer defensible medicine. The formal recognition of cardiovascular-kidney-metabolic (CKM) syndrome as a unified clinical entity reshapes how clinicians should screen, stratify risk, and intervene — with the kidney now positioned as a central organizing axis rather than a downstream casualty.
The American Heart Association's 2023 designation of CKM syndrome marked a conceptual turning point, acknowledging that CKD, obesity, type 2 diabetes, hypertension, dyslipidemia, and cardiovascular disease are biologically and clinically inseparable. This review in Kidney International maps how the Kidney Disease: Improving Global Outcomes (KDIGO) organization has systematically built a guideline architecture around this interconnected pathophysiology. The framework spans existing clinical practice guidelines on CKD, blood pressure control, diabetes management, and lipid-lowering, while an anticipated heart failure–CKD guideline and controversy reports on obesity and CKD prevention round out the suite. Key themes running through all documents include early detection, personalized cardiometabolic risk management, and mandating multidisciplinary care teams.
The clinical significance here extends beyond guideline bookkeeping. CKM syndrome affects an estimated one in three U.S. adults when all staging criteria are applied, making this one of the highest-burden disease clusters in modern medicine. KDIGO's renal-centric lens is strategically important because kidney function decline often precedes overt cardiovascular events and frequently goes undetected in primary care settings. The rise of SGLT2 inhibitors and GLP-1 receptor agonists — agents that simultaneously address renal, glycemic, and cardiovascular endpoints — gives this framework urgent practical grounding. Limitations of the review are inherent to its nature as a narrative synthesis of existing guidelines rather than original clinical data; implementation gaps across health systems and resource-limited settings remain a substantial challenge. Still, the consolidation of KDIGO guidance under the CKM umbrella represents a meaningful organizational advance, signaling that siloed nephrology, cardiology, and endocrinology care models are clinically obsolete.